|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combining genetic characterization with the immunogenicity of merozoite surface protein-8 (MSP-8) supports considering MSP-8 as a candidate target for blood-stage vaccines against malaria.
|
30975200 |
2019 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
The effect of biannual versus annual azithromycin distribution for trachoma control on serological response to merozoite surface protein 1 (MSP-1<sub>19</sub>), a surrogate for malaria incidence, was evaluated among children in Niger.
|
31796025 |
2019 |
|
Malaria
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Epidemiology of malaria and MSP-2 gene-based genetic diversity of <i>Plasmodium falciparum</i> from patients attending community health centre, Jiribam, Manipur.
|
29063888 |
2018 |
|
Malaria
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Merozoite surface protein 7 (MSP-7) is a multigene family expressed during malaria blood-stage infection.
|
29718980 |
2018 |
|
Malaria
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These data suggest that AMA-1 and MSP-1<sub>19</sub> sero-epidemiological analysis may provide further evidence in assessing variation in malaria exposure and evaluating malaria control efforts in high endemic area.
|
28831122 |
2017 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to assess the immune responses against Plasmodium falciparum merozoite surface protein-1 (MSP-1<sub>19</sub>) and apical membrane antigen-1 (AMA-1) in children residing in the different epidemiological strata of malaria in Cameroon.
|
29121929 |
2017 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several studies of P. falciparum have reported that the C-terminus (a 42kDa fragment) of merozoite surface protein-1 (MSP-1<sub>42</sub>; consisting of MSP-1<sub>19</sub> and MSP-1<sub>33</sub>) is a potential candidate for a malaria vaccine.
|
28634105 |
2017 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data suggest that MSP-1, especially the partially conserved subunit MSP-1<sub>83</sub>, is a major target of opsonizing antibodies acquired during natural exposure to malaria.
|
28877929 |
2017 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
A pool of human plasma from a malaria endemic region was collected from 140 single plasma donations selected for reactivity to Plasmodium falciparum apical membrane antigen-1 (AMA-1) and merozoite surface proteins (MSP-1<sub>19</sub>, MSP-1<sub>42</sub>, MSP-2 and MSP-3).
|
28779755 |
2017 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study determines whether the presence of malaria and intestinal parasites co-infection is associated with impaired IgG responses to Plasmodium vivax AMA-1 and MSP-119 in a rural population of the Brazilian Amazon.
|
26546161 |
2015 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
A longitudinal study was conducted in a low endemic area in northern Tanzania to examine the influence of the α-thalassaemia trait on malaria incidence and antibody responses to malaria apical membrane antigen-1 (AMA-1) and merozoite surface protein1-19 (MSP-119).
|
25604491 |
2015 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
In most of the earlier studies, the MSP-142 of malaria parasites was expressed as insoluble protein in inclusion bodies and it is difficult to get purified protein in conformation form.
|
25195175 |
2014 |
|
Malaria
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The major MSP-119 haplotypes of P. falciparum populations in all endemic populations during three transmission seasons in Thailand were identified, providing basic information on the common haplotypes of MSP-119 that is of use for malaria vaccine development and inferring the population structure of P. falciparum populations in Thailand.
|
24521474 |
2014 |
|
Malaria
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Except for children under 3 years, the age-matched proportions of children achieving protective threshold concentrations of antibodies against AMA1 and MSP-2 were significantly lower in Junju compared to Chonyi (Fishers exact test, P<0.01).
|
23800539 |
2013 |
|
Malaria
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In order to characterize and investigate the extent and maintenance of MSP-9 genetic diversity, we analyzed DNA sequences of the following malaria parasite species: Plasmodium falciparum, Plasmodium reichenowi, Plasmodium chabaudi, Plasmodium yoelii, Plasmodium berghei, Plasmodium coatneyi, Plasmodium gonderi, Plasmodium knowlesi, Plasmodium inui, Plasmodium simiovale, Plasmodium fieldi, Plasmodium cynomolgi and Plasmodium vivax and evaluated the signature of natural selection in all MSP-9 orthologs.
|
24044894 |
2013 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Antibody elution efficiency was assessed by total IgG ELISA for malaria antigens apical membrane antigen-1 (AMA-1) and merozoite-surface protein-1 (MSP-142).
|
23914905 |
2013 |
|
Malaria
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These data suggest that inclusion of more than one MSP-119 variant may not be required in a malaria blood stage vaccine.
|
22909378 |
2012 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Merozoite surface protein-1 (MSP-1) and MSP-2 of Plasmodium falciparum are potential vaccine candidate antigens for malaria vaccine development.
|
20478015 |
2010 |
|
Malaria
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Parasitemia at the time of diagnosis, rather than cumulative malaria exposure or acquired immunity (presence of variant-specific antibodies matching the MSP-2 type in infecting parasites), was a major predictor of perceived symptom severity.
|
17556615 |
2007 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
The genetic polymorphism of the surface merozoite protein 2 (MSP-2) was evaluated in Plasmodium falciparum isolates from individuals with uncomplicated malaria living in a Brazilian endemic area of Peixoto de Azevedo.
|
12880589 |
2003 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
(3) The overall pattern of human IgG antibody responses to MSP-2 in Karitiana Indians, a population continuously exposed to hypoendemic malaria in the Brazilian Amazon Region, differs from that described in hyperendemic areas in Africa and Papua New Guinea in two important features: there was no clear age-dependent increase in the prevalence and mean concentration of specific IgG antibodies, and there was no skewing towards the IgG3 subclass in antibody responses.
|
11596920 |
2002 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Blood samples were collected from 142 patients with symptomatic malaria and typed using a polymerase chain reaction-based strategy for merozoite surface protein-(MSP-1) block 2, the MSP-2 central domain, and glutamate-rich protein (GLURP) repeat domain polymorphism.
|
10674682 |
1999 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Structural diversity in a 45 kDa surface antigen on Plasmodium falciparum merozoites (termed GYMSSA, MSP-2 or MSA-2) and other candidate molecules for developing a malaria vaccine need to be investigated in parasites obtained directly from patients in different malaria endemic countries.
|
7918680 |
1994 |